Provided by Tiger Fintech (Singapore) Pte. Ltd.

Viking Therapeutics

23.09
-0.6000-2.53%
Post-market: 23.170.0782+0.34%17:37 EDT
Volume:4.98M
Turnover:116.87M
Market Cap:2.60B
PE:-15.02
High:24.14
Open:23.61
Low:22.96
Close:23.69
52wk High:81.73
52wk Low:18.92
Shares:112.44M
Float Shares:109.98M
Volume Ratio:0.97
T/O Rate:4.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5368
EPS(LYR):-1.0085
ROE:-19.99%
ROA:-14.99%
PB:3.26
PE(LYR):-22.90

Loading ...

Earnings Flash:(VKTX) Viking Therapeutics Q2 Loss $0.58 Vs. FactSet Est. $0.45 Loss

MT Newswires Live
·
Jul 24

Stock Track | Viking Therapeutics Plunges 5.09% After-Hours on Q2 Earnings Miss

Stock Track
·
Jul 24

Stock Track | Viking Therapeutics Plunges 5.09% After-Hours on Q2 Earnings Miss and Wider Net Loss

Stock Track
·
Jul 24

Viking Therapeutics Q2 net loss widens, misses expectations

Reuters
·
Jul 24

Viking Therapeutics Q2 EPS $(0.58) Misses $(0.46) Estimate

Benzinga
·
Jul 24

Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Jul 24

Viking Therapeutics Q2 Operating Expenses USD 74.574 Million

THOMSON REUTERS
·
Jul 24

Lilly and Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns. -- Barrons.com

Dow Jones
·
Jul 04

Greg Zante, CFO, Reports Disposal of Common Shares of Viking Therapeutics Inc

Reuters
·
Jul 04

Marianna Mancini, COO of Viking Therapeutics Inc., Reports Disposal of Common Shares

Reuters
·
Jul 04

Viking Therapeutics Inc. Publishes Corporate Presentation Highlighting Advances in Metabolic and Endocrine Disease Therapeutics

Reuters
·
Jul 03

BUZZ-U.S. STOCKS ON THE MOVE-Coinbase, Rubrik, AeroVironment

Reuters
·
Jun 26

Viking Therapeutics Price Target Maintained With a $102.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 25

BUZZ-U.S. STOCKS ON THE MOVE-Array Technologies, Viking Therapeutics, Winnebago

Reuters
·
Jun 25

BUZZ-Viking Therapeutics rises after it starts late-stage study of obesity drug

Reuters
·
Jun 25

Viking Therapeutics Initiates Phase 3 Clinical Program for Obesity Treatment with Dual Agonist VK2735

Reuters
·
Jun 25

Viking Therapeutics Inc. Unveils Presentation on Advancements in Obesity and Metabolic Disease Treatments

Reuters
·
Jun 14

Ascletis Pharma Faces Legal Setback with Seven-Year Exclusion Order for ASC41 and ASC43F Drugs

Reuters
·
May 30

Viking Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
May 28

Viking Therapeutics Inc. Unveils Corporate Presentation on Advancements in Metabolic and Endocrine Disease Therapies

Reuters
·
May 02